Skip to search formSkip to main contentSkip to account menu

CR011-vcMMAE

Known as: Antibody-Drug Conjugate CR011-vcMMAE, CR011-vcMMAE Immunotoxin 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
glembatumumab vedotin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma.
9032 Background: GPNMB is expressed on melanoma cells and represents a potential target for ADCs. CR011-vcMMAE is a fully-human… 
2016
2016
Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma.
9063 Background: CR011-vcMMAE, an ADC of fully-human monoclonal anti-GPNMB antibody (Ab) with monomethylauristatin E (MMAE), is… 
2016
2016
A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC).
1067 Background: Glycoprotein NMB (GPNMB), also known as osteoactivin, has been shown to regulate metastasis of breast cancer in… 
2013
2013
CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE)
The development of monoclonal antibodies as cancer therapeutic agents has improved the outlook for many patients as evidenced by… 
2009
2009
A Phase (Ph) I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients (Pts) with Locally Advanced or Metastatic Breast Cancer (MBC).
Background: Glycoprotein NMB (GPNMB), also known as osteoactivin, is expressed in 25-40% of breast cancers and is associated with… 
2008
2008
A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma
9029 Background: Glycoprotein NMB (GPNMB) is highly expressed in melanoma. CR011-vcMMAE is comprised of a human monoclonal… 
2007
2007
A phase I and pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III /IV melanoma
B47 Background: Glycoprotein NMB (GPNMB) expression on the cell surface of melanoma cells is substantially greater than most… 
2006
2006
Cancer Therapy : Preclinical
Purpose: Advanced melanoma is a highly drug-refractory neoplasm representing a significant unmet medical need.We sought to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)